Cite
HARVARD Citation
Smolen, J. et al. (2016). Head-to-head comparison of certolizumab pegol versus adalimumab in rheumatoid arthritis: 2-year efficacy and safety results from the randomised EXXELERATE study. Lancet. 388 (10061), pp. 2763-2774. [Online].